Climb Bio, Inc. (NASDAQ:CLYM – Get Free Report) dropped 8% during trading on Thursday. The stock traded as low as $11.23 and last traded at $11.2650. 255,008 shares changed hands during trading, a decline of 76% from the average daily volume of 1,069,229 shares. The stock had previously closed at $12.25.
Wall Street Analyst Weigh In
CLYM has been the subject of a number of research reports. BTIG Research reissued a “buy” rating and issued a $32.00 target price on shares of Climb Bio in a report on Tuesday, October 27th. Royal Bank Of Canada initiated coverage on shares of Climb Bio in a research report on Monday, August 3rd. They set an “outperform” rating and a $23.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Climb Bio in a research report on Thursday, October 15th. B. Riley Financial reissued a “buy” rating on shares of Climb Bio in a research note on Friday, September 4th. Finally, Mizuho upgraded shares of Climb Bio to a “strong-buy” rating in a research report on Wednesday, September 16th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $28.14.
Read Our Latest Research Report on CLYM
Climb Bio Price Performance
The company has a fifty day moving average price of $11.75 and a two-hundred day moving average price of $10.57. The company has a market capitalization of $646.12 million, a P/E ratio of -13.40 and a beta of 0.01.
Climb Bio (NASDAQ:CLYM – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02. As a group, sell-side analysts forecast that Climb Bio, Inc. will post -0.75 earnings per share for the current year.
Insider Activity at Climb Bio
In related news, Director Stephen Thomas sold 100,000 shares of the business’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $13.67, for a total value of $1,367,000.00. Following the sale, the director owned 467,969 shares of the company’s stock, valued at $6,397,136.23. The trade was a 17.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 2.60% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the stock. First Trust Advisors LP bought a new position in shares of Climb Bio during the third quarter worth about $490,000. State Street Corp lifted its stake in shares of Climb Bio by 34.7% in the third quarter. State Street Corp now owns 1,850,010 shares of the company’s stock worth $21,220,000 after acquiring an additional 476,466 shares during the period. Fisher Asset Management LLC bought a new stake in Climb Bio in the third quarter valued at approximately $505,000. Nan Fung Trinity HK Ltd. boosted its holdings in Climb Bio by 212.3% in the third quarter. Nan Fung Trinity HK Ltd. now owns 360,654 shares of the company’s stock valued at $4,137,000 after acquiring an additional 245,160 shares during the last quarter. Finally, Fifth Third Bancorp boosted its holdings in Climb Bio by 10.1% in the third quarter. Fifth Third Bancorp now owns 181,510 shares of the company’s stock valued at $2,082,000 after acquiring an additional 16,587 shares during the last quarter. 69.76% of the stock is owned by institutional investors and hedge funds.
Climb Bio Company Profile
Climb Bio is a clinical-stage biopharmaceutical company developing treatments for autoimmune and inflammatory diseases, with a focus on conditions involving B cells and antibody production. Its lead candidate, budoprutug, is an antibody designed to engage CD19 and FcγRIIb to inhibit B-cell activity. The company is evaluating the candidate in clinical studies for immune-mediated diseases, including immune thrombocytopenia and membranous nephropathy. Climb Bio is also developing CLYM-116, an antibody targeting APRIL, a protein involved in B-cell and antibody activity.
Featured Stories
- Five stocks we like better than Climb Bio
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
- Midterm Fallout, NVIDIA Turmoil, Anthropic’s IPO: Is Broadcom a Steal?
- 3 Pharmaceutical Stocks That Offer Safety and Growth
- If Japan’s Stock Market Rally Returns, These 3 ETFs Could Benefit
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
